The telehealth and wellness stock tanked more than 12% Aug. 5, a day after posting mixed Q2 earnings. More importantly, Bank ...

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucrative market for weight loss drugs.

European giant Novo Nordisk vowed to lower prices for its popular weight-loss drug to reach more U.S. customers.

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst ...

With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect ...

Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a higher risk of muscle loss and reduced mobility.

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Novo Nordisk, the Danish drugmaker behind the popular obesity drug Wegovy, warns of fierce competition and market pressures, potentially leading to layoffs. As compounders produce cheaper copycats, U.